Supplementary figures



Suppl. fig. 1 Kifunensine inhibits ERAD of CD147 in HeLa cells. HeLa cells were treated with kifunensine for 72 hours and CD147 was visualized on western blot. GAPDH was used as a loading control. Con: Control, Kif: Kifunensine.



Suppl. fig. 2 Kifunensine reduces UPR activation and UPR mediated cytotoxicity in HeLa cells. HeLa cells were preconditioned with kifunensine (1 µg/mL) for 72 hours. Cells were treated with tunicamycin (as indicated) and kifunensine for 20 hours. Induction of the UPR was assessed by qPCR analysis of BiP mRNA. Shown are mean and SD in arbitrary units (AU; *n*=3, ** indicates a statistical difference of P≤0.01). MTT viability assay was performed to assess tunicamycin induced cytotoxicity in the absence or presence of kifunensine preconditioning (1 µg/mL, 72 hours). Shown are mean and SEM values normalized to control (*n*=6, statistical differences at a significance level of P≤0.001 are indicated by ***).



Suppl. fig. 3 Preconditioning is required for the protective effect of kifunensine. Cells were treated with kifunensine and tunicamycin at the indicated concentrations for 20 hours. MTT viability assay was performed to assess tunicamycin induced cytotoxicity in the absence or presence of kifunensine preconditioning (1 µg/mL, 72 hours). Shown are mean and SEM values normalized to control (*n*=6, statistical differences at a significance level of P≤0.05 are indicated by *). Control: No kifunensine treatment, kifunensine: 72 hours preconditioning and 20 hours co-treatment with kifunensine and tunicamycin, no preconditioning: 20 hours co-treatment with tunicamycin and kifunensine.